Anandamide Tolerance Transferred to Cannabinoids but Not Tested Opioids in Mice
Mice tolerant to injected anandamide showed cross-tolerance to THC and CP55,940 but not to the tested opioid agonists. The pattern differed from the THC-related cross-tolerance described in the same research context.
The challenge measured a spinal pain response
Repeated systemic anandamide exposure preceded intrathecal testing with a tail-flick endpoint. The anandamide dose-response curve shifted toward higher doses. Endogenous origin does not make this administration physiological: the experiment repeatedly injected the ligand and used a localized challenge route.
Cross-tolerance was selective across drug classes
Anandamide-tolerant mice showed cross-tolerance to THC and CP55,940. They did not show it to the tested mu-, delta- or kappa-opioid agonists, including dynorphins. These negative opioid comparisons limit an explanation based on a general reduction in responsiveness to every antinociceptive drug.
THC and anandamide were not mechanistically interchangeable
The authors contrasted this pattern with cross-tolerance from THC to cannabinoid and kappa-agonist effects. They proposed differences involving endogenous dynorphin systems. That interpretation does not identify one complete pathway or establish the same interaction under every dosing history.
This experiment is especially useful for assessing the direction and scope of cross-tolerance. A shared cannabinoid-related effect did not imply identical opioid interactions. The findings do not establish clinical pain-treatment equivalence or predict whether cannabis exposure changes an individual patient's response to an opioid.
Related: interpreting cannabis tolerance claims.
Research cited
Welch SP. Characterization of anandamide-induced tolerance: comparison to delta 9-THC-induced interactions with dynorphinergic systems. Drug and alcohol dependence (1997). doi:10.1016/s0376-8716(97)01342-2. Findings discussed from the study abstract.
